RNA editing is the next frontier in gene therapy – here’s what you need to know
- Written by Flora Hui, Research Fellow, Centre for Eye Research Australia and Honorary Fellow, Department of Surgery (Ophthalmology), The University of Melbourne
IoanaB/ShutterstockThe United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.
This trial marks a new frontier in gene therapy –...





